Transcriptional control of cardiac fuel metabolism and mitochondrial function

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 76, Issue , 2011, Pages 175-182

  Leone, T C ^a   Kelly, D P ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA;

AORTA CONSTRICTION; ARTICLE; BIOGENESIS; CONGESTIVE CARDIOMYOPATHY; DOWN REGULATION; ENERGY TRANSFER; FUNCTIONAL STATUS; GENE DISRUPTION; GENE EXPRESSION; GENE REGULATORY NETWORK; GENETIC DISORDER; GLUCOSE OXIDATION; GLUCOSE UTILIZATION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INNATE IMMUNITY; INSULIN RESISTANCE; LIPID STORAGE; MECHANICAL STRESS; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PERINATAL PERIOD; PHENOTYPE; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; DIABETES MELLITUS; ENERGY METABOLISM; GENE TARGETING; HEART HYPERTROPHY; MITOCHONDRIAL BIOGENESIS; MYOCARDIAL DISEASE; PROTEIN DEPLETION;

ANIMALS; ENERGY METABOLISM; GENE EXPRESSION REGULATION; HUMANS; MITOCHONDRIA, HEART; MYOCARDIUM; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84867421344     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2011.76.011965     Document Type: Article

References (69)

1. Alaynick WA, Kondo RP, Xie W, He W, Dufour CR, Downes M, Jonker JW, Giles W, Naviaux RK, Giguere V, Evans RM. 2007. ERRg directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6: 13-24.
2. Andersson U, Scarpulla RC. 2001. Pgc-1-related coactivator, a novel, serum-inducible coactivator of nuclear respiratory factor 1-dependent transcription in mammalian cells. Mol Cell Biol 21: 3738-3749.
3. Anversa P, Loud AV, Giacomelli F, Wiener J. 1978. Absolute morphometric study of myocardial hypertrophy in experimental hypertension. II. Ultrastructure of myocytes and interstitium. Lab Invest 38: 597-609.
4. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. 2006. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-g coactivator 1a. Proc Natl Acad Sci 103: 10086-10091.
5. Belke DD, Larsen TS, Gibbs EM, Severson DL. 2000. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 279: E1104-E1113.
6. Carley AN, Severson DL. 2005. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 1734: 112-126.
7. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, Schaffer JE. 2001. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107: 813-822.
8. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. 2002. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40: 271-277.
9. de las Fuentes L, Herrero P, Peterson LR, Kelly DP, Gropler RJ, Davila-Roman VG. 2003. Myocardial fatty acid metabolism: Independent predictor of left ventricular mass in hypertensive heart disease. Hypertension 41: 83-87.
10. de Roos A, Doornbos J, Luyten PR, Oosterwaal LJ, van derWall EE, den Hollander JA. 1992. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: Assessment with proton-decoupled P-31 MR spectroscopy. J Magn Reson Imaging 2: 711-719.
11. DiMauro S, Schon EA. 2001. Mitochondrial DNA mutations in human disease. Am J Med Genet 106: 18-26.
12. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. 2007. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-a/PGC-1a gene regulatory pathway. Circulation 115: 909-917.
13. Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, Courtois MR, Lavine KJ, Goldberg IJ, Kelly DP. 2010. Rescue of cardiomyopathy in peroxisome proliferatoractivated receptor-a transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-a activators. Circulation 121: 426-435.
14. Finck BN, Kelly DP. 2002. Peroxisome proliferator-activated receptor a (PPARa) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 34: 1249-1257.
15. Finck BN, Kelly DP. 2006. PGC-1 coactivators: Inducible regulators of energy metabolism in health and disease. J Clin Invest 116: 615-622.
16. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. 2002. The cardiac phenotype induced by PPARa overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121-130.
17. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. 2003. A critical role for PPARamediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content. Proc Natl Acad Sci 100: 1226-1231.
18. Ge K, Cho YW, Guo H, Hong TB, Guermah M, Ito M, Yu H, Kalkum M, Roeder RG. 2008. Alternative mechanisms by which mediator subunit MED1/TRAP220 regulates peroxisome proliferator-activated receptor g-stimulated adipogenesis and target gene expression. Mol Cell Biol 28: 1081-1091.
19. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, Heldmaier G, Maier R, Theussl C, Eder S, et al. 2006. Defective lipolysis and altered energymetabolism inmice lacking adipose triglyceride lipase. Science 312: 734-737.
20. Handschin C, Spiegelman BM. 2006. Peroxisome proliferatoractivated receptor g coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27: 728-735.
21. Hansson A, Hance N, Dufour E, Rantanen A, Hultenby K, Clayton DA, Wibom R, Larsson NG. 2004. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proc Natl Acad Sci 101: 3136-3141.
22. Huss JM, Torra IP, Staels B, Giguere V, Kelly DP. 2004. Estrogen-related receptor a directs peroxisome proliferatoractivated receptor a signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol 24: 9079-9091.
23. Huss JM, Imahashi K, Dufour CR, Weinheimer CJ, Courtois M, Kovacs A, Giguere V, Murphy E, Kelly DP. 2007. The nuclear receptor ERRa is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab 6: 25-37.
24. Iemitsu M, Miyauchi T, Maeda S, Sakai S, Kobayashi T, Fujii N, Miyazaki H, Matsuda M, Yamaguchi I. 2001. Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. Am J Physiol Regul Integr Comp Physiol 281: R2029-R2036.
25. Ingwall JS, Weiss RG. 2004. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circul Res 95: 135-145.
26. Ingwall JS, Kramer MF, Fifer MA, Lorell BH, Shemin R, Grossman W, Allen PD. 1985. The creatine kinase system in normal and diseased human myocardium. New Engl J Med 313: 1050-1054.
27. Kayar SR, Weiss HR. 1992. Diffusion distances, total capillary length and mitochondrial volume in pressure-overload myocardial hypertrophy. J Mol Cell Cardiol 24: 1155-1166.
28. Kelly DP, Scarpulla RC. 2004. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev 18: 357-368.
29. Kelly DP, Strauss AW. 1994. Inherited cardiomyopathies. New Engl J Med 330: 913-919.
30. Kirby DM, Salemi R, Sugiana C, Ohtake A, Parry L, Bell KM, Kirk EP, Boneh A, Taylor RW, Dahl HH, et al. 2004. NDUFS6 mutations are a novel cause of lethal neonatal mitochondrial complex I deficiency. J Clin Invest 114: 837-845.
31. Kressler D, Schreiber SN, Knutti D, Kralli A. 2002. The PGC-1-related protein PERC is a selective coactivator of estrogen receptor a. J Biol Chem 277: 13918-13925.
32. Lai L, Leone TC, Zechner C, Schaeffer PJ, Kelly SM, Flanagan DP, Medeiros DM, Kovacs A, Kelly DP. 2008. Transcriptional coactivators PGC-1a and PGC-lb control overlapping programs required for perinatal maturation of the heart. Genes Dev 22: 1948-1961.
33. Larsson NG, Oldfors A. 2001. Mitochondrial myopathies. Acta Physiol Scand 171: 385-393.
34. Lehman JJ, Kelly DP. 2002. Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart. Clin Exp Pharmacol Physiol 29: 339-345.
35. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. 2000. Peroxisome proliferator-activated receptor g coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106: 847-856.
36. Lelliott CJ, Medina-Gomez G, Petrovic N, Kis A, Feldmann HM, Bjursell M, Parker N, Curtis K, Campbell M, Hu P, et al. 2006. Ablation of PGC-1b results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS Biol 4: e369.
37. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, et al. 2005. PGC-1a deficiency causes multisystem energy metabolic derangements: Muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3: e101.
38. Li H, Wang J, Wilhelmsson H, Hansson A, Thoren P, Duffy J, Rustin P, Larsson NG. 2000. Genetic modification of survival in tissue-specific knockout mice with mitochondrial cardiomyopathy. Proc Natl Acad Sci 97: 3467-3472.
39. Lin J, Puigserver P, Donovan J, Tarr P, Spiegelman BM. 2002. Peroxisome proliferator-activated receptor g coactivator 1b (PGC-1b), a novel PGC-1-related transcription coactivator associated with host cell factor. J Biol Chem 277: 1645-1648.
40. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, Mootha VK, Jager S, Vianna CR, Reznick RM, et al. 2004. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1a null mice. Cell 119: 121-135.
41. Lin J, Handschin C, Spiegelman BM. 2005. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1: 361-370.
42. Lu Z, Xu X, Hu X, Fassett J, Zhu G, Tao Y, Li J, Huang Y, Zhang P, Zhao B, Chen Y. 2010. PGC-1 a regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxid Redox Signal 13: 1011-1022.
43. Neely JR, Rovetto MJ, Oram JF. 1972. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 15: 289-329.
44. Neubauer S. 2007. The failing heart-An engine out of fuel. New Engl J Med 356: 1140-1151.
45. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. 1997. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96: 2190-2196.
46. Paulson DJ, Crass MF 3rd. 1982. Endogenous triacylglycerol metabolism in diabetic heart. Am J Physiol 242: H1084- H1094.
47. Puigserver P, Spiegelman BM. 2003. Peroxisome proliferatoractivated receptor-g coactivator 1 a (PGC-1 a): Transcriptional coactivator and metabolic regulator. Endocr Rev 24: 78-90.
48. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. 1998. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92: 829-839.
49. Riehle C, Wende AR, Zaha VG, Pires KM, Wayment B, Olsen C, Bugger H, Buchanan J, Wang X, Moreira AB, et al. 2011. PGC-1b deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Circul Res doi: 101161/CircResaha.III.243964.
50. Rodrigues B, Cam MC, McNeill JH. 1995. Myocardial substrate metabolism: Implications for diabetic cardiomyopathy. J Mol Cell Cardiol 27: 169-179.
51. Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, Saffitz JE, Medeiros DM, Valencik ML, McDonald JA, Kelly DP. 2004. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor g coactivator-1a promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circul Res 94: 525-533.
52. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. 1996. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94: 2837-2842.
53. Sack MN, Disch DL, Rockman HA, Kelly DP. 1997. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc Natl Acad Sci 94: 6438-6443.
54. Sano M, Wang SC, Shirai M, Scaglia F, Xie M, Sakai S, Tanaka T, Kulkarni PA, Barger PM, Youker KA, et al. 2004. Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. EMBO J 23: 3559-3569.
55. Schilling J, Lai L, Sambandam N, Dey CE, Leone TC, Kelly DP. 2011. Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor fgg coactivator-1 signaling. Circul Heart Fail 4: 474-482.
56. Sihag S, Cresci S, Li AY, Sucharov CC, Lehman JJ. 2009. PGC-1a and ERRa target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol 46: 201-212.
57. Sonoda J, Mehl IR, Chong LW, Nofsinger RR, Evans RM. 2007. PGC-1b controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis. Proc Natl Acad Sci 104: 5223-5228.
58. Stanley WC, Lopaschuk GD, McCormack JG. 1997. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34: 25-33.
59. Strom CC, Aplin M, Ploug T, Christoffersen TE, Langfort J, Viese M, Galbo H, Haunso S, Sheikh SP. 2005. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J 272: 2684-2695.
60. Taegtmeyer H, Golfman L, Sharma S, Razeghi P, van Arsdall M. 2004. Linking gene expression to function: Metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci 1015: 202-213.
61. Tian R, Nascimben L, Kaddurah-Daouk R, Ingwall JS. 1996. Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. J Mol Cell Cardiol 28: 755-765.
62. Vakili BA, Okin PM, Devereux RB. 2001. Prognostic implications of left ventricular hypertrophy. Am Heart J 141: 334-341.
63. van Bilsen M, Smeets PJ, Gilde AJ, van der Vusse GJ. 2004. Metabolic remodelling of the failing heart: The cardiac burnout syndrome? Cardiovasc Res 61: 218-226.
64. Vega RB, Huss JM, Kelly DP. 2000. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor a in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 20: 1868-1876.
65. Wallace DC. 1999. Mitochondrial diseases in man and mouse. Science 283: 1482-1488.
66. Weiss RG, Gerstenblith G, Bottomley PA. 2005. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci 102: 808-813.
67. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, et al. 2003. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111: 419-426.
68. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, Febbraio M, Finck BN, Kelly DP. 2007. CD36 deficiency rescues lipotoxic cardiomyopathy. Circul Res 100: 1208-1217.
69. Zechner C, Lai L, Zechner JF, Geng T, Yan Z, Rumsey JW, Collia D, Chen Z, Wozniak DF, Leone TC, Kelly DP. 2010. Total skeletal muscle PGC-1 deficiency uncouples mitochondrial derangements from fiber type determination and insulin sensitivity. Cell Metab 12: 633-642.